Q1 2025 Urogen Pharma Ltd Earnings Call Transcript
Key Points
- UGN-102 is in the final stages of FDA review with a PDUFA target date of June 13, indicating potential near-term approval.
- The ENVISION trial showed an 80.6% complete response rate at 18 months, highlighting the drug's efficacy.
- UGN-102 is expected to be a primary growth driver, with a market opportunity of over $5 billion, significantly larger than the Jelmyto market.
- UroGen Pharma Ltd (URGN) is expanding its sales force from 50 to over 80 reps in anticipation of UGN-102's launch.
- The company has a strong balance sheet with over $200 million in cash equivalents and marketable securities as of March 31, 2025.
- UGN-102's approval is based on a single-arm study, which may raise concerns about the comparability of results.
- The company reported a net loss of $43.8 million for the first quarter of 2025, an increase from the previous year.
- R&D expenses increased due to higher manufacturing costs and costs associated with the Phase 3 utopia trial for UGN-103.
- The gross-to-net rate for Jelmyto has been a headwind, although it is expected to stabilize.
- The company anticipates a temporary miscellaneous J-code for UGN-102, which may impact initial adoption rates.
Hello and welcome to UroGen Pharma first quarter 2025 earnings conference call. (Operator Instructions)I would now like to turn the conference over to Vincent Perrone. You may begin.
Thank you, operator. Good morning, everyone, and welcome to UroGen Pharma's first quarter 2025 financial results and business update conference call. Earlier this morning, we issued a press release providing an overview of our recent corporate highlights and financial results for the quarter ended March 31, 2025.
The press release can be accessed on the investors portion of our website at investors.UroGen.com. Joining me on the call today are Liz Barrett, President and Chief Executive Officer; Doctor Mark Schoenberg, Chief Medical Officer; David Lin, Chief Commercial Officer; and Chris Degnan, Chief Financial Officer.
During today's call, we will be making certain forward-looking statements. These may include statements regarding our ongoing pre-commercialization activities related to UGN-102, regulatory
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
